Dr Sudheer Moorkoth
Professor & Head of the Department
Date of Joining: 18.07.2008
Department of Pharmaceutical Quality Assurance
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
Sudheer Moorkoth teaches undergraduate and postgraduate students.
SUBJECTS CURRENTLY TEACHING
| Subject | Semester / Year |
|---|---|
| Pharmaceutical Analysis-I Theory | BPharm- First semester |
| Pharmaceutical Analysis-I Lab | BPharm- First semester |
| Clinical Research Regulations | MPharm- First semester |
| Regulatory Affairs practicals | MPharm- First semester |
ACADEMIC QUALIFICATIONS
| Degree | Specialisation | Institute | Year of passing |
|---|---|---|---|
| Ph.D. | Manipal Academy of Higher Education | 2009 | |
| MPharm (Master of Pharmacy) | Pharmaceutical Chemistry | MGR Medical University | 2002 |
| BPharm (Bachelor of Pharmacy) | Bangalore University | 1993 |
Experience
| Institution / Organisation | Designation | Role | Tenure |
|---|---|---|---|
| Department of Pharmaceutical Quality Assurance, MCOPS, Manipal Academy of Higher Education | Assistant professor | 2009-2012 | |
| Department of Pharmaceutical Quality Assurance, MCOPS, Manipal Academy of Higher Education | Lecturer | 2008-2009 | |
| School of Medical Education, Mahatma Gandhi University, Kottayam | Lecturer, Senior lecturer |
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Expertise
Organic synthesis Docking and QSAR studies Structural interpretation using various spectral techniques such as UV, IR, MS and NMR. Biological screening in the area such as anticancer, anti-inflammatory, and antimicrobial activities. Analytical method development using HPLC, GC-MS, UV
Professional Affiliations & Contributions
Analytical Chemistry: Dr. Sudheer Moorkoth is also involved in developing analytical techniques using HPLC, GC-MS and LC-MS for drugs and other molecules. It includes pre-clinical and clinical studies. He conducts research on drug metabolism, pharmacokinetics and toxicological analysis. He is also involved in the biomarker profiling for various inborn errors of metabolism (IEM).
Synthetic chemistry: Dr. Sudheer Moorkoth also has expertise in the synthesis, characterization and biological evaluation of various heterocyclic molecules. He has synthesized and characterized forty novel aminoflavones. Expertise in the biological activity evaluation includes antioxidant activity, anticancer activity and anti-inflammatory activity.
The author credentials and citation graphs can be accessed by following platforms,
Scopus author ID: 35574376800
ORCID ID: orcid.org/0000-0002-5341-0981
Google scholar link:
https://scholar.google.co.in/citations?view_op=list_works&hl=en&user=8dPf2cwAAAAJ
Peer review record can be verified at:
PUBLON ID: https://publons.com/author/736629/sudheer-moorkoth#profile
Life Member of Indian Pharmaceutical Association, 2004.
Work Experience
| Organisation | Role | Tenure |
|---|---|---|
| Johnson and Johnson India Limited | Professional Service Executive Sales and after sales service |
Synthesis and anti-cancer activity of novel thiazolidinone analogs of 6-aminoflavone
Sudheer Moorkoth
Chemical and Pharmaceutical Bulletin of Japan, Vol. 63, (2010)
Synthesis, in vitro anticancer and antioxidant activity of thiadiazole substituted thiazolidin-4-ones
Chaitanyakumar Shah Angel Treasa Alex Naseer Maliyakkal Sudheer Moorkoth Jessy Elizabeth Mathew
Acta Pharmaceutica, Vol. 63, (2013)
Evaluation of Chemical Interactions of Maleic Acid with Sodium Hypochlorite and Chlorhexidine Gluconate
Nidambur Vasudev Ballal Sudheer Moorkoth Kundabala Mala Kadengodlu Seetharama Bhat Syed Sajjad Hussen Shriram Pathak
Journal of Endodontics, Vol. 37, (2011)
Synthesis and evaluation of a series of novel imidazolidinone analogues of 6-aminoflavone as anticancer and anti-inflammatory agents
Sudheer Moorkoth Srinivasan K.K Naseer M.
Med Chem Res, Vol. 22, (2013)
High-Performance Liquid Chromatographic Assay for Ziprasidone in Plasma Samples: Application to Pharmacokinetic Studies in Rats
Swapnil Marghade Prashant B. Musmade Sudheer Moorkoth
Journal of Chromatographic Sciences, Vol.50, (2012)
Development and validation of RP-HPLC method for estimation of lafutidine in bulk drug and in solid dosage forms
2012-01-01 Sunny Kumar
(M Pharm), 2012, Second Year. Developed a novel analytical method for estimation of lafutidine in bulk drug and in solid dosage form. The developed method is very economical, simple. The method is fully validated as per the ICH guidelines. The method was used successfully for the stability testing of Lafutidine at various stress conditions.
Development and validation of stability indicating assay method for effaverinz in bulk drug using reverse phase high performance liquid chromatography
2011-01-01 Asish Dubey
2011, Second Year. Effaverinz is an anti-HIV drug. An analytical method was developed for the estimation of Effaverinz in bulk drug, using HPLC method, which can be used with LC-MS. The developed method was compatible with LC-MS for estimation as well as for the determination of stability at various stress conditions. Additionally the method is able to predict various degradation products from the mass spectra of the degradation products.
Development of quality management systems (QMS) in PERD centre and evaluation of quality assurance activity in analytical lab
2010-01-01 Swapnil Merghade
(M Pharm), 2010. The project was performed at PERD centre Ahmedabad. The project aimed at evaluating the present quality assurance activity at PERD centre and to suggest various changes. A quality Management System was developed for the PERD centre.
Regulatory frame work in implementation of ICH Q9 guidelines”,
2012-01-01 Amrita Das
(MSc in Pharmaceutical Regulatory Affairs), 2012. A possibility for the implementation of quality risk management at pharmaceutical industry was studied. After reviewing the ICH and PICS guidelines various suggestions were proposed for implementing the QRM and thus to reduce the risk and loses and time delays for a company which ultimately leads to profit for a company.
Biosimilars registration requirements in US and Europe and the fate of Indian companies
2011-01-01 Yogesh Gujar
(MSc in Pharmaceutical Regulatory Affairs), 2011. Biosimilars are the generic versions of biologic drugs. There are differences in regulations due to the complexity of the biologics. The work analyses various regulations put forward by USFDA, EMEA and CDSCO, and concludes on the possibility of Indian companies to tap the profitable bio similar market in US and EU.